Dupixent Receives FDA Approval for Treating Bullous Pemphigoid in Adults

The US FDA has approved Dupixent (dupilumab) for the treatment of adult patients with bullous pemphigoid, a rare and chronic skin disease affecting approximately 27,000 adults in the US. The approval is based on pivotal results showing improvements in durable disease remission and reductions in itching and oral corticosteroid use compared to placebo. Dupixent is now approved in the US for eight distinct diseases with type 2 underlying inflammation, including skin, intestinal, and respiratory diseases affecting a wide range of patients.